#cagrilintide 2025-08-04

while im here if youre used to GLP-1 titration steps this feels absurdly cautious and i still do it that way, for what its worth

thats the phase 3 one

is the weekly schedule the same here

the slower titration in here is community habit as much as anything, the trials had their own schedule

monotherapy was underwhelming for me and i say that as someone who wanted it to work

noticed something around week 20 on monotherapy, well after i had given up expecting to, n of 1 obviously

went slower because the first step gave me two rough days and i took that as information, we shall see

held mine a while

fullness rather than nausea

combination GI was worse than either alone for me, which is not what i had read anywhere

the reason nausea reads differently is timing, mine arrived on the second day rather than the first, ill dig out the number

while im here changed my mind on this, i started thinking amylin was the interesting bit and now i think its the pairing

Verification log updated: QYB — evidence added, status unchanged.

its an amylin analogue, different receptor family, so treating it as another GLP-1 is the first mistake

ok so REDEFINE is the phase 3 programme, most of what gets quoted casually in here is earlier work, i could be wrong

the combination is the thing with trial data behind it, monotherapy in here is mostly us guessing

ok so the fullness effect hasnt faded over 13 months, unlike my semaglutide appetite curve

lost 102lb over 25 months on the combination and i genuinely cannot apportion it

added it to an existing semaglutide dose rather than starting both, which made attribution possible

anyone got two Medutest results on the same CPC lot for this

Purity check: no report on file for lot H-2814. Nothing logged either way.

nobody should copy my schedule, im describing it because people asked what a slow ramp looks like

is 2.4 the number for this too or am i confusing compounds